LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ

Creative Commons License

Rutten G. E. H. M., Tack C. J., Pieber T. R., ÇÖMLEKÇİ A., Orsted D. D., Baeres F. M. M., ...More

DIABETOLOGY & METABOLIC SYNDROME, vol.8, 2016 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2016
  • Doi Number: 10.1186/s13098-016-0153-5
  • Journal Name: DIABETOLOGY & METABOLIC SYNDROME
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Type 2 diabetes, External validity, Generalizability, Cardiovascular outcome trial, Heterogeneity
  • Open Archive Collection: AVESIS Open Access Collection
  • Dokuz Eylül University Affiliated: Yes

Abstract

Aims: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity.